The effect of n-3 fatty acids and coenzyme Q10 supplementation on neutrophil leukotrienes, mediators of inflammation resolution and myeloperoxidase in chronic kidney disease

被引:37
作者
Barden, Anne E. [1 ]
Shinde, Sujata [1 ]
Burke, Valerie [1 ]
Puddey, Ian B. [1 ]
Beilin, Lawrence J. [1 ]
Irish, Ashley B. [1 ]
Watts, Gerald F. [1 ]
A. Mori, Trevor [1 ]
机构
[1] Univ Western Australia, Sch Med, Med Res Fdn Bldg,GPO BOX X2213, Perth, WA, Australia
基金
英国医学研究理事会;
关键词
Leukotrienes; n-3 fatty acids; Myeloperoxidase; Specialised proresolving lipid mediators; Neutrophils; RANDOMIZED CONTROLLED-TRIAL; 20-HYDROXYEICOSATETRAENOIC ACID; BLOOD-PRESSURE; 5-LIPOXYGENASE; B-4; GRANULOCYTES; METABOLITES; LEUKOCYTES; REDUCTION; PRODUCTS;
D O I
10.1016/j.prostaglandins.2018.03.002
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Neutrophils release leukotriene (LT)B-4 and myeloperoxidase (MPO) that may be important mediators of chronic inflammation in chronic kidney disease (CKD). The n-3 fatty acids (n-3 FA) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have the potential to attenuate inflammation through production of LTBs and the Specialized Proresolving Lipid Mediators (SPM) that promote the resolution of inflammation. In animal models, coenzyme Q10 (CoQ) also attenuates inflammation by reducing MPO and LTB4. Objective: This study evaluated the independent and combined effects of n-3 FA and CoQ supplementation on neutrophil leukotrienes, the pro-inflammatory eicosanoid 5-hydroxyeicosatetraenoic acid (5-HETE), SPM, and plasma MPO, in patients with CKD. Design: In a double-blind, placebo-controlled intervention of factorial design, 85 patients with CKD were randomized to either n-3 FA (4 g), CoQ (200 mg), both supplements, or control (4 g olive oil), daily for 8 weeks. Plasma MPO and calcium ionophore-stimulated neutrophil release of LTs, 5-HETE and SPM were measured at baseline and after 8 weeks. Results: Seventy four patients completed the intervention. n-3 FA, but not CoQ, significantly increased neutrophil LTBs (P < 0.0001) and the SPM 18-hydroxyeicosapentaenoic acid (18-HEPE), resolvin E1(RvE1), resolvin E2 (RvE2) and resolvin E3 (RvE3) that derive from EPA, as well as 17-hydroxydocosahexaenoic acid (17-HDHA) and resolvin D5 (RvD5) that derive from DHA (all P < 0.01). Neutrophil LTB4 and its metabolites, and 5-HETE were not significantly altered by n-3 FA or CoQ. Plasma MPO was significantly reduced with n-3 FA alone (P = 0.013) but not when given in combination with CoQ. Conclusion: n-3 FA supplementation in patients with CKD leads to increased neutrophil release of LTBs and several SPM, as well as a reduction in plasma MPO that may have important implications for limiting chronic inflammation.
引用
收藏
页码:1 / 8
页数:8
相关论文
共 36 条
[1]   Update on Inflammation in Chronic Kidney Disease [J].
Akchurin, Oleh M. ;
Kaskel, Frederick .
BLOOD PURIFICATION, 2015, 39 (1-3) :84-92
[2]   THE EFFECT OF N-3 FATTY ACIDS ON PLASMA MYELOPEROXIDASE LEVELS IN HEALTHY ADULTS [J].
Andersen, V. L. ;
Vogt, J. ;
Obel, T. ;
Christensen, J. H. ;
Schmidt, E. B. .
CELLULAR AND MOLECULAR BIOLOGY, 2010, 56 (01) :3-9
[3]  
[Anonymous], OXID MED CELL LONGEV
[4]   Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation [J].
Arita, Makoto ;
Ohira, Taisuke ;
Sun, Yee-Ping ;
Elangovan, Siva ;
Chiang, Nan ;
Serhan, Charles N. .
JOURNAL OF IMMUNOLOGY, 2007, 178 (06) :3912-3917
[5]   n-3 Fatty Acid Supplementation and Leukocyte Telomere Length in Patients with Chronic Kidney Disease [J].
Barden, Anne ;
O'Callaghan, Nathan ;
Burke, Valerie ;
Mas, Emile ;
Beilin, Lawrence J. ;
Fenech, Michael ;
Irish, Ashley B. ;
Watts, Gerald F. ;
Puddey, Ian B. ;
Huang, Rae-Chi ;
Mori, Trevor A. .
NUTRIENTS, 2016, 8 (03)
[6]   Short-term n-3 fatty acid supplementation but not aspirin increases plasma proresolving mediators of inflammation [J].
Barden, Anne ;
Mas, Emilie ;
Croft, Kevin D. ;
Phillips, Michael ;
Mori, Trevor A. .
JOURNAL OF LIPID RESEARCH, 2014, 55 (11) :2401-2407
[7]   n-3 fatty acids reduce plasma 20-hydroxyeicosatetraenoic acid and blood pressure in patients with chronic kidney disease [J].
Barden, Anne E. ;
Burke, Valerie ;
Mas, Emilie ;
Beilin, Lawrence J. ;
Puddey, Ian B. ;
Watts, Gerald F. ;
Irish, Ashley B. ;
Mori, Trevor A. .
JOURNAL OF HYPERTENSION, 2015, 33 (09) :1947-1953
[8]  
BOYUM A, 1974, TISSUE ANTIGENS, V4, P269
[9]  
Boyum A, 1968, Scand J Clin Lab Invest Suppl, V97, P7
[10]  
Chiang N., 2013, FASEB J, P27